Any antidepressant drug ends up being a $2 billion drug at least, but we've seen the depression market really slow down. It's a big, [but] lackluster market. |
I think they're relatively cheap. What we saw was a big run-up toward April, and now we're seeing a little more profit-taking. |
I would expect costs to rise as the year goes on. They shifted some savings into this quarter. |
If I was one of the attorneys suing Merck, I would be very excited about this. It would imply that the company actively omitted data in a public forum, trying to make their product look better. |
It makes sense, after losing a big case like the one in Texas. But it doesn't sound like many cases will fall into that category. |
Merck right now is going to fight cases. But obviously, if there's thousands and thousands of cases, they'll end up not being able to fight all of them. They will have to settle some of them. |
Most of the bad things are happening now, and things do get brighter at the end of the decade. They are still a lot people on the sidelines who would rather wait and miss a little bit of run-up, but get confirmation [later on] that those stocks are going to strengthen. |
Other companies facing top line pressures are going to have to cut costs. |
The early cases are important in determining the value per claimant. If they're only allowed to defend hard cases in the beginning, that makes it more difficult for them to produce a low settlement. |